GlobeNewswire by notified

UK Biobank Pharma Proteomics Project publishes early results from its pioneering proteomics research

Share

UPPSALA, Sweden, June 21, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) announced that a publication describing the early findings of proteomics research conducted by the UK Biobank Pharma Proteomics Project (UKB-PPP) was published online to the bioRxiv preprint server, and is available here.

The study, titled “Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants,” utilized Olink® Explore 1536 and genome sequencing on 54,306 UK Biobank participants to gather and analyze data from protein quantitative trait loci (pQTL) mapping of 1,463 proteins identifying 10,248 primary genetic associations, of which 85% have not been previously reported.

The results from the UKB-PPP publication provide an updated genetic atlas of the plasma proteome and provide the scientific community with an open-access, population-scale proteomics resource of unprecedented breadth and depth to help elucidate biological mechanisms underlying genetic discoveries. Measuring thousands of proteins at population scale has promise to improve our understanding of underlying mechanisms of disease, and therefore accelerate the development of novel biomarkers and therapeutics. Furthermore, the study highlights the strengths of Olink’s Explore assay for pQTL detection and downstream biological discovery, with a high proportion, 82% of the proteins tested, having cis associations, evidence of Olink’s highly specific assays that measure their intended proteins.

“The landmark research conducted by members of the UKB-PPP is a meaningful early step in harnessing the power of next-generation proteomics in combination with genetic information to improve human health," said Jon Heimer, CEO of Olink. "We are extraordinarily grateful that Olink’s Explore platform can be part of this tremendous journey, and eagerly await the full data set to be released to the scientific community by the end of this year."

The UK Biobank Pharma Proteomics Project is a collaboration between UK Biobank and thirteen biopharmaceutical companies, and is currently performing one of the world’s largest scientific studies of blood protein biomarkers. The UK Biobank is a large-scale, biomedical database and research resource containing in-depth genetic and health information from half a million UK participants. The database is globally accessible to approved researchers and scientists undertaking vital research into the most common and life-threatening diseases. UKB-PPP aims to enable better understanding of disease biology and support innovative drug development for more effective therapies.

Olink Investor Contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com

Olink Media Contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com

About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden. Learn more about Olink here.

Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our 2022 revenue outlook, our Explore externalizations, our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under the caption "Risk Factors" in our Form 20-F (Commission file number 001-40277) and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections for the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Vaisala's Half Year Financial Report January–June 2022 to be published on July 22, 20226.7.2022 14:30:00 CEST | Press release

Vaisala Corporation Press release July 6, 2022, at 3:30 p.m. (EEST) Vaisala's Half Year Financial Report January–June 2022 to be published on July 22, 2022 Vaisala Corporation will publish its Half Year Financial Report January–June 2022 on Friday, July 22, 2022, at about 9:00 a.m. (Finnish time). The report will be available at vaisala.com/investors. The President and CEO's presentation will be published by 1:00 p.m. on the same day at vaisala.com/investors. Audiocast and conference call An audiocast and a conference call for analysts, investors and media will be held in English on the same day starting at 1:00 p.m. (Finnish time). Numbers for conference call, during which questions may be presented, are: Finland: +358 9 8171 0310 UK: +44 33 3300 0804 Sweden: +46 8 5664 2651 US: +1 63 1913 1422 PIN: 25951253# A link to the live audiocast will be available at vaisala.com/investors. A recording will be available on the website later the same day. More information Paula Liimatta, Busines

Synthesio introduces Topic Modeling, an AI-powered trend discovery engine6.7.2022 14:00:00 CEST | Press release

NEW YORK, July 06, 2022 (GLOBE NEWSWIRE) -- Synthesio, a social listening pioneer and AI-enabled consumer intelligence leader, today announced the general release of a ground-breaking solution: Topic Modeling. This artificial intelligence (AI) -powered discovery engine, automatically scans, categorizes, and visualizes hundreds of thousands of online conversations in only a few clicks using the power of machine learning. Topic Modeling detects consumer-defined themes, uncovers unknown or hidden phenomena, and makes trend analysis easier. “Consumer trends emerge, take hold, then go out of style or evolve faster than most marketers and insights pros can keep up with. For those tasked with understanding consumers, this has increased the pressure to move even faster, anticipate behavioral shifts, and spot trend signals as they emerge. To meet our clients’ new needs, we evolved our solution beyond tracking consumer posts, to actually identifying net-new insights and ideas,” said Synthesio CE

Press- och analytikermöte6.7.2022 09:30:00 CEST | Pressemelding

Fredagen den 22 juli 2022, kl. 08:00, publiceras Bilias delårsrapport för andra kvartalet 2022. Samma dag arrangerar Bilia press- och analytikermöte via Financial Hearings, där CEO Per Avander och CFO Kristina Franzén presenterar rapporten och svarar på frågor. Presentationen börjar kl. 09:00. För att delta, vänligen ring in via telefonnummer eller följ presentationen på webblänk enligt nedan. Telekonferens: Ring in på tfn: 08 - 505 163 86 och ange PIN-kod: 7163030# För att följa sändningen på webben: https://financialhearings.com/event/44350 Göteborg den 6 juli 2022 Bilia AB (publ) För information vänligen kontakta: Carl Fredrik Ewetz, Investor Relations, 010-497 07 73, carl.fredrik.ewetz@bilia.se Per Avander, VD och koncernchef, 010-497 70 00, per.avander@bilia.se Kristina Franzén, CFO, 010-497 73 40, kristina.franzen@bilia.se Fakta om Biliakoncernen Bilia är en av Europas största bilåterförsäljare med en ledande position inom service och försäljning av personbilar, transportbilar oc

Press and analyst meeting6.7.2022 09:30:00 CEST | Press release

On Friday July 22, 2022, at 08:00 CEST, Bilia’s report for the second quarter 2022 will be published. On the same day Bilia arranges press and analyst meetings via Financial Hearings, where CEO Per Avander and CFO Kristina Franzén will present the report and answer questions. The presentation starts at 09:00 (CEST). To participate, please call in via telephone number or follow the presentation on the web link as below. Telephone conference: Dial-in number: SE +46 850516386, UK +44 2031984884, US +1 4123176300 and enter PIN code: 7163030# Follow the presentation on the web link: https://financialhearings.com/event/44350 Gothenburg, July 6, 2022 Bilia AB (publ) For information please contact: Carl Fredrik Ewetz, Investor Relations, +46 (0)10 497 07 73, carl.fredrik.ewetz@bilia.se Per Avander, Managing Director and CEO, +46 (0)10 497 70 00, per.avander@bilia.se Kristina Franzén, CFO, +46 (0)10 497 73 40, kristina.franzen@bilia.se Facts about the Bilia Group Bilia is one of Europe’s larges

Cargotec’s January–June 2022 half year financial report to be published on Wednesday, 20 July 20226.7.2022 08:30:00 CEST | Press release

CARGOTEC CORPORATION, PRESS RELEASE, 6 JULY 2022 AT 9:30 AM (EEST) Cargotec’s January–June 2022 half year financial report to be published on Wednesday, 20 July 2022 Cargotec Corporation will publish its January–June 2022 half year financial report on Wednesday, 20 July 2022 at approximately 1:30 p.m. EEST. The report will be available at www.cargotec.com after publication. A live international telephone conference for analysts, investors and media will be arranged on the publishing day at 3:00 p.m. EEST. The event will be held in English. The report will be presented by CEO Mika Vehviläinen and CFO Mikko Puolakka. The presentation material will be available at www.cargotec.com by latest 2:30 p.m. EEST. The telephone conference, during which questions may be presented, can be accessed with code 914555 by calling one of the following numbers: Finland +358 (0)9 7479 0572 France +33 (0)1 70 730 3 37 Germany +49 (0)69 22222 5195 Singapore +65 6703 6923 Sweden +46 (0)8 5664 2754 Switzerland